TICKER: OBD EXCHANGE: AIM
Oxford Biodynamics plc is an AIM listed, revenue generating biotechnology company discovering and developing epigenetic markers. Its proprietary technology platform, EpiSwitch, aims to discover chromosome conformation signatures that can accelerate drug discovery and development, increase success rates and optimise personalised medicine.
Published: Dec 16 2019
Oxford Biodynamics’ EpiSwitch platform has won widespread recognition this year, including a fifth immune-oncology (IO) collaboration and involvement in two clinical trials in ALS and prostate cancer. Its YE’19 financials provided further evidence of ongoing revenue generation whilst investing in increased capacity for additional collaborations, particularly in the IO space. As well as the company gaining the Queen’s Award for Enterprise, EpiSwitch is being used to prospectively identify and measure biomarkers in a partner’s clinical study.